

DAFTAR PUSTAKA

- A. Soslow, R., Soerjomataram, I., Campbell, I., & Malpica, A. (2020). *High-grade serous carcinoma of the ovary*. In: *WHO Classification of Tumours Editorial Board. Female genital tumours [Internet]* (5th ed., Vol. 4). International Agency for Research on Cancer. <https://tumourclassification.iarc.who.int/chaptercontent/34/13>
- Amin, N. H., Ahmed, B. A., Abou-Bakr, A. A., Eissa, S. S., Nassar, H. R., Gad, M., & Eissa, M. (2023). The Impact of BRCA1 Expression on Survival Status in Ovarian Serous Carcinoma of Egyptian Patients. *Asian Pacific Journal of Cancer Prevention*, 24(10), 3613–3620. <https://doi.org/10.31557/APJCP.2023.24.10.3613>
- Arney, K. (2015). *Shape-shifting molecular cousins are the key to DNA repair - Cancer Research UK - Cancer News*. Cancer Research UK. <https://news.cancerresearchuk.org/2015/07/20/shape-shifting-molecular-cousins-are-the-key-to-dna-repair/>
- Bradbury, M., Borràs, E., Castellví, J., Méndez, O., Sánchez-Iglesias, J. L., Pérez-Benavente, A., Gil-Moreno, A., Sabidó, E., & Santamaria, A. (2022). BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling. *Scientific Reports*, 12(1), 4445. <https://doi.org/10.1038/s41598-022-08461-0>
- Brzovic, P. S., Rajagopal, P., Hoyt, D. W., King, M., & Klevit, R. E. (2001). Structure of a BRCA1 – BARD1 heterodimeric RING – RING complex © 2001 Nature Publishing Group <http://structbio.nature.com>. *Nature Structural Biology*, 833–837.
- Budiana, I. N. G., & Angelina, M. (2019). Ovarian cancer : Pathogenesis and current recommendations for prophylactic surgery. *Journal Of The Turkish-German Gynecological Association*, 20(1), 47–54. <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>

- Casey, L., & Singh, N. (2019). Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes. *Surgical Pathology Clinics*, 12(2), 515–528. <https://doi.org/10.1016/j.path.2019.01.007>
- Chao, A., Chang, T., Lapke, N., Jung, S., Chi, P., Chen, C., Yang, L., Lin, C., & Huang, H. (2016). Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. *Oncotarget*, 7(51), 85529–85541.
- Chen, M., Jin, Y., Bi, Y., Li, Y., Shan, Y., & Pan, L. (2015). Prognostic Significance of Lymphovascular Space Invasion in Epithelial Ovarian Cancer. *J Cancer*, 6, 412–419. <https://doi.org/10.7150/jca.11242>
- Choi, Y. E., Meghani, K., Brault, M.-E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., Shih, K. K., Matulonis, U., Levine, D. A., Konstantinopoulos, P. A., & Chowdhury, D. (2016). Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. *Cell Reports*, 14(3), 429–439. <https://doi.org/10.1016/j.celrep.2015.12.046>
- De Leo, A., Santini, D., Ceccarelli, C., Santandrea, G., Palicelli, A., Acquaviva, G., Chiarucci, F., Rosini, F., Ravegnini, G., Pession, A., Turchetti, D., Zamagni, C., Perrone, A. M., De Iaco, P., Tallini, G., & de Biase, D. (2021). What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. *Diagnostics*, 11(4). <https://doi.org/10.3390/diagnostics11040697>
- den Brok, W. D., Schrader, K. A., Sun, S., Tinker, A. V., Zhao, E. Y., Aparicio, S., & Gelmon, K. A. (2017). Homologous Recombination Deficiency in Breast Cancer: A Clinical Review. *JCO Precision Oncology*, 1, 1–13. <https://doi.org/10.1200/po.16.00031>
- Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M.,

- Znaor, A., & Bray, F. (2024). *Global Cancer Observatory: Cancer Today (version 1.1)*. <https://gco.iarc.who.int/today/en>
- Garg, K., Levine, D. A., Olvera, N., Dao, F., Bisogna, M., Secord, A. A., Berchuck, A., Cerami, E., Schultz, N., & Soslow, R. A. (2013a). BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas. *The American Journal of Surgical Pathology*. <https://doi.org/10.1097/pas.0b013e31826cabbd>
- Garg, K., Levine, D. A., Olvera, N., Dao, F., Bisogna, M., Secord, A. A., Berchuck, A., Cerami, E., Schultz, N., & Soslow, R. A. (2013b). BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. *The American Journal of Surgical Pathology*, 37(1), 138–146. <https://doi.org/10.1097/PAS.0b013e31826cabbd>
- Gilchrist, D. A. (2025). Mutation. In *Talking Glossary of Genomic and Genetic Terms*. National Human Genome Research Institute (NHGRI). <https://www.genome.gov/genetics-glossary/Mutation>
- Guo, T., Dong, X., Xie, S., Zhang, L., Zeng, P., & Zhang, L. (2021). Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. *Cancer Management and Research*, 13, 3081–3100. <https://doi.org/10.2147/CMAR.S292992>
- Heriyanto, D. S. (2022). *BRCA1 MUTATION TEST IN OVARIAN CANCER: MOLECULAR PATHOLOGY ASPECT*.
- Hintzsche, J. D., Robinson, W. A., & Tan, A. C. (2016). A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. *International Journal of Genomics*, 2016. <https://doi.org/10.1155/2016/7983236>
- JL, M., DM, H., Garg, K., Zhou, Q., Dao, F., Bisogna, M., Gao, J., ND, S., RN, G., Phillips, M., Iasonos, A., ND, K., DA, L., RA, S., & DR, S. (2014). The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade

serous ovarian cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 25(12), 2372–2378. <https://doi.org/10.1093/annonc/mdu461>

Kalachand, R. D., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E. L., Ruscito, I., Braicu, E. I., Sehouli, J., Ignatov, A., Yu, H., Katsaros, Di., Mills, G. B., Lu, K. H., Carey, M. S., Timms, K. M., Kupryjanczyk, J., Rzepecka, I. K., Podgorska, A., ... Hennessy, B. T. (2020). BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. *Journal of the National Cancer Institute*, 112(12), 1190–1203. <https://doi.org/10.1093/jnci/djaa070>

Kashima, K., Oite, T., Aoki, Y., Takakuwa, K., Aida, H., Nagata, H., Sekine, M., Wu, H. J., Hirai, Y., Wada, Y., Yamamoto, K., Hasegawa, K., Sonoda, T., Maruo, T., Nagata, I., Ohno, M., Suzuki, M., Kohayashi, I., Kuzuya, K., ... Tanaka, K. (2000). Screening of BRCA1 mutation using immunohistochemical staining with C- terminal and N-terminal antibodies in familial ovarian cancers. *Japanese Journal of Cancer Research*, 91(4), 399–409. <https://doi.org/10.1111/j.1349-7006.2000.tb00959.x>

Khashaba, M., Fawzy, M., Abdel-Aziz, A., Eladawei, G., & Nagib, R. (2022). Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach. *Journal of the Egyptian National Cancer Institute*, 34(1). <https://doi.org/10.1186/s43046-022-00104-9>

Köbel, M., & Kang, E. Y. (2022). The Evolution of Ovarian Carcinoma Subclassification. *Cancers*, 14(2), 1–16. <https://doi.org/10.3390/cancers14020416>

Konecny, G. E., & Kristeleit, R. S. (2016). PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. *British Journal of Cancer*, 115(10), 1157–1173. <https://doi.org/10.1038/bjc.2016.311>

- Kroeger, P. T., & Drapkin, R. (2017). Pathogenesis and heterogeneity of ovarian cancer. *Current Opinion in Obstetrics and Gynecology*, 29(1), 26–34. <https://doi.org/10.1097/GCO.0000000000000340>
- Kumar, V., Abbas, A. K., Aster, J. C., Cotran, R. S., & Robbins, S. L. (Stanley L. (2020). *Robbins & Cotran pathologic basis of disease 10th Edition* (Tenth Edit). Elsevier.
- Kurman, R. J., & Shih, I.-M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm. *Human Pathology*, 42(7), 918–931. <https://doi.org/https://doi.org/10.1016/j.humpath.2011.03.003>
- Kurman, R. J., & Shih, I.-M. (2016). The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. *The American Journal of Pathology*, 186(4), 733–747. <https://doi.org/10.1016/j.ajpath.2015.11.011>
- Lisio, M. A., Fu, L., Goyeneche, A., Gao, Z. H., & Telleria, C. (2019). High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. *International Journal of Molecular Sciences*, 20(4). <https://doi.org/10.3390/ijms20040952>
- Liu, J., Hu, H. H., Lee, M. H., Korenaga, M., Jen, C. L., Batrla-Utermann, R., Lu, S. N., Wang, L. Y., Mizokami, M., Chen, C. J., & Yang, H. I. (2017). Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. *Scientific Reports*, 7(1), 1–10. <https://doi.org/10.1038/s41598-017-14747-5>
- Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. *Science*, 355(6330), 1152–1158. <https://doi.org/10.1126/science.aam7344>
- Lorenzini, J., Deberti, M., Body, G., Carcopino, X., Touboul, C., Dabi, Y., Collinet, P., Coutant, C., Akladios, C., Lavoué, V., Bolze, P.-A., Huchon, C., Bricou, A., Canlorbe, G., Mimoun, C., Bendifallah, S., &

- Ouldamer, L. (2022). Lymphovascular space invasion and estrogen receptor status in high-grade serous ovarian cancer - A multicenter study by the FRANCOGYN group. *Journal of Gynecology Obstetrics and Human Reproduction*, 51(1), 102242. <https://doi.org/10.1016/j.jogoh.2021.102242>
- Mafficini, A., Simbolo, M., Parisi, A., Rusev, B., Luchini, C., Cataldo, I., Piazzola, E., Sperandio, N., Turri, G., Franchi, M., Tortora, G., Bovo, C., Lawlor, R. T., & Scarpa, A. (2016). BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. *Oncotarget*, 7(2), 1076–1083. <https://doi.org/10.18632/oncotarget.6834>
- Mahdi, H., Hafez, N., Doroshov, D., Sohal, D., Keedy, V., Do, K. T., LoRusso, P., Jürgensmeier, J., Avedissian, M., Sklar, J., Glover, C., Felicetti, B., Dean, E., Mortimer, P., Shapiro, G. I., & Eder, J. P. (2021). Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). *JCO Precision Oncology*, 5. <https://doi.org/10.1200/PO.20.00439>
- Manchana, T., Tantbirojn, P., & Pohthipornthawat, N. (2020). BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients. *Gynecologic Oncology Reports*, 33, 100582. <https://doi.org/10.1016/j.gore.2020.100582>
- Martínez-Chantar, M. L., Avila, M. A., & Lu, S. C. (2020). Hepatocellular carcinoma: Updates in pathogenesis, detection and treatment. *Cancers*, 12(10), 1–4. <https://doi.org/10.3390/cancers12102729>
- Matsuo, K., Yoshino, K., Hiramatsu, K., Banzai, C., Hasegawa, K., Yasuda, M., Nishimura, M., Sheridan, T. B., Ikeda, Y., Shiki, Y., Mabuchi, S., Enomoto, T., Kimura, T., Fujiwara, K., Roman, L. D., & Sood, A. K. (2014). Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. *Obstetrics and Gynecology*, 123(5), 957–965.

<https://doi.org/10.1097/AOG.0000000000000240>

- Meisel, J. L., Hyman, D. M., Garg, K., Zhou, Q., Dao, F., Bisogna, M., Gao, J., Schultz, N. D., Grisham, R. N., Phillips, M., Iasonos, A., Kauff, N. D., Levine, D. A., Soslow, R. A., & Spriggs, D. R. (2014). The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 25(12), 2372–2378. <https://doi.org/10.1093/annonc/mdu461>
- Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018). PARP Inhibitors in Ovarian Cancer. *Recent Patents on Anti-Cancer Drug Discovery*, 13(4), 392–410. <https://doi.org/10.2174/1574892813666180305165256>
- Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016). Hereditary breast and ovarian cancer: new genes in confined pathways. *Nature Reviews. Cancer*, 16(9), 599–612. <https://doi.org/10.1038/nrc.2016.72>
- Olsen, C. M., Nagle, C. M., Whiteman, D. C., Ness, R., Pearce, C. L., Pike, M. C., Rossing, M. A., Terry, K. L., Wu, A. H., Risch, H. A., Yu, H., Doherty, J. A., Chang-Claude, J., Hein, R., Nickels, S., Wang-Gohrke, S., Goodman, M. T., Carney, M. E., Matsuno, R. K., ... Webb, P. M. (2013). Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*, 20(2), 251–262. <https://doi.org/10.1530/ERC-12-0395>
- Otsuka, I. (2021). Mechanisms of high-grade serous carcinogenesis in the fallopian tube and ovary: Current hypotheses, etiologic factors, and molecular alterations. *International Journal of Molecular Sciences*, 22(9). <https://doi.org/10.3390/ijms22094409>
- Pan, C., Xu, S., Li, L., & Lin, A. (2025). BRCA1 expression in ovarian cancer and its relationship with clinicopathological characteristics and prognosis. *Scientific Reports*, 15(1). <https://doi.org/10.1038/s41598->

025-06390-2

- Peres, L. C., Cushing-Haugen, K. L., Anglesio, M., Wicklund, K., Bentley, R., Berchuck, A., Kelemen, L. E., Nazeran, T. M., Gilks, C. B., Harris, H. R., Huntsman, D. G., Schildkraut, J. M., Rossing, M. A., Köbel, M., & Doherty, J. A. (2018). Histotype classification of ovarian carcinoma: A comparison of approaches. *Gynecologic Oncology*, *151*(1), 53–60. <https://doi.org/10.1016/j.ygyno.2018.08.016>
- Peres, L., Cushing-Haugen, K., Anglesio, M., Wicklund, K., Bentley, R., Berchuck, A., Kelemen, L. E., Nazeran, T. M., Gilks, C. B., Harris, H. R., Huntsman, D. G., Schildkraut, J. M., Rossing, M. A., Köbel, M., & Doherty, J. A. (2018). Histotype classification of ovarian carcinoma: A comparison of approaches. *Gynecologic Oncology*, *151*(1), 53–60. <https://doi.org/10.1016/j.ygyno.2018.08.016>
- Prat, J. (2014). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics*, *124*(1), 1–5. <https://doi.org/10.1016/j.ijgo.2013.10.001>
- Punzón-Jiménez, P., Lago, V., Domingo, S., Simón, C., & Mas, A. (2022). Molecular Management of High-Grade Serous Ovarian Carcinoma. *International Journal of Molecular Sciences*, *23*(22), 1–30. <https://doi.org/10.3390/ijms232213777>
- Rosen, E. M., Fan, S., & Ma, Y. (2006). BRCA1 regulation of transcription. *Cancer Letters*, *236*(2), 175–185. <https://doi.org/https://doi.org/10.1016/j.canlet.2005.04.037>
- Schoutrop, E., Moyano-Galceran, L., Lheureux, S., Mattsson, J., Lehti, K., Dahlstrand, H., & Magalhaes, I. (2022). Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. *Seminars in Cancer Biology*, *86*(Pt 3), 207–223. <https://doi.org/10.1016/j.semcancer.2022.03.027>
- Singer, G., Kurman, R. J., Chang, H.-W., Cho, S. K. R., & Shih, I.-M. (2002).

Diverse tumorigenic pathways in ovarian serous carcinoma. *The American Journal of Pathology*, 160(4), 1223–1228. [https://doi.org/10.1016/s0002-9440\(10\)62549-7](https://doi.org/10.1016/s0002-9440(10)62549-7)

Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012). Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. *Modern Pathology*, 25(4), 625–636. <https://doi.org/https://doi.org/10.1038/modpathol.2011.183>

Strachan, T., Goodship, J., & Chinnery, P. (2015). Genetics and Genomics in Medicine. In *European Journal of Human Genetics* (1st ed., Vol. 23, Issue 5). Garland Science. <http://www.garlandscience.com>

Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D'Andrea, A. D., Matulonis, U. A., & Konstantinopoulos, P. A. (2016). Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. *Oncotarget*, 7(12), 13587–13598. <https://doi.org/10.18632/oncotarget.7277>

Sugino, K., Tamura, R., Nakaoka, H., Yachida, N., Yamaguchi, M., Mori, Y., Yamawaki, K., Suda, K., Ishiguro, T., Adachi, S., Isobe, M., Yamaguchi, M., Kashima, K., Motoyama, T., Inoue, I., Yoshihara, K., & Enomoto, T. (2019). Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. *Scientific Reports*, 9(1), 17808. <https://doi.org/10.1038/s41598-019-54116-y>

Takaoka, M., & Miki, Y. (2018). BRCA1 gene: function and deficiency. *International Journal of Clinical Oncology*, 23(1), 36–44. <https://doi.org/10.1007/s10147-017-1182-2>

Tarsounas, M., & Sung, P. (2020). The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication. *Nature Reviews Molecular Cell Biology*, 21(5), 284–299. <https://doi.org/10.1038/s41580-020-0218-z>

- Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018). Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. *Medicines (Basel, Switzerland)*, 5(1). <https://doi.org/10.3390/medicines5010016>
- Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., Traficante, N., Fereday, S., Hung, J. A., Chiew, Y. E., Haviv, I., Gertig, D., Defazio, A., & Bowtell, D. D. L. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. *Clinical Cancer Research*, 14(16), 5198–5208. <https://doi.org/10.1158/1078-0432.CCR-08-0196>
- Turashvili, G., Lazaro, C., Ying, S., Charames, G., Wong, A., Hamilton, K., Yee, D., Agro, E., Chang, M., Pollett, A., & Lerner-Ellis, J. (2020). Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. *Cancers*, 12(11). <https://doi.org/10.3390/cancers12113468>
- UCSC. (2025, August). *UCSC Genome Browser on Human*. https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr17%3A41170763-41292367&hgid=2942236402_sGUuv5dvmQm5zAip8tKa58aC24QZ
- van der Groep, P., van der Wall, E., & van Diest, P. J. (2011). Pathology of hereditary breast cancer. *Cellular Oncology (Dordrecht)*, 34(2), 71–88. <https://doi.org/10.1007/s13402-011-0010-3>
- varsome. (2025). *Transcript Details BRCA1*. <https://varsome.com/transcript/hg38/ENST00000357654.9>
- World Health Organization. (2018). Factsheet 2018 Indonesia. *Framework Convention on Tobacco Control*, 1–36.
- Wu, Y., Xu, S., Cheng, S., Yang, J., & Wang, Y. (2023). Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. *Journal of Ovarian Research*, 16(1), 6.

<https://doi.org/10.1186/s13048-023-01094-5>

Zarei, S., Wang, Y., Jenkins, S. M., Voss, J. S., Kerr, S. E., & Bell, D. A. (2020). Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. *The American Journal of Surgical Pathology*, *44*(3), 316–328. <https://doi.org/10.1097/PAS.0000000000001419>

Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D. A., & Neel, B. G. (2019). Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. *Nature Communications*, *10*(1). <https://doi.org/10.1038/s41467-019-13116-2>

Zouzoulas, D., Tsolakidis, D., Tzitzis, P., Chatzistamatiou, K., Theodoulidis, V., Sofianou, I., Grimbizis, G., & Timotheadou, E. (2024). CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study. *International Journal of Molecular Sciences*, *25*(10). <https://doi.org/10.3390/ijms25105230>

Lampiran 1: Dokumentasi Kegiatan



Pembuatan unstain slide (RSWS)



Persiapan Pewarnaan IHC BRCA1



Proses Pewarnaan IHC BRCA1

Lampiran 2: Lembar Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agusalm Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 612/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 9 Agustus 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24060462	No Sponsor	
Peneliti Utama	dr. Fathurrahman Muiz, M.Biomed	Sponsor	
Judul Peneliti	ANALISIS HUBUNGAN KLINIKOPATOLOGIS DAN MUTASI BRCA1 PADA PASIEN HIGH GRADE SEROUS CARCINOMA OVARIVM		
No Versi Protokol	1	Tanggal Versi	21 Juni 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP. Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 9 Agustus 2024 sampai 9 Agustus 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan